July 2, 2019

Patented technology applied in SynGEM, a needle-free nasal spray vaccine against respiratory syncytial virus


Re-Issuance of U.S. Patent No. RE 47,471 further bolsters Mucosis’ intellectual property portfolio

Groningen / Odijk, The Netherlands, July 2, 2019 –  The trustee of biotech company Mucosis B.V., Mr. Holtz LLM and Virtuvax B.V. today announce that the US Patent Office (USPTO) has issued patent RE.  47,471 dated July 2, 2019. The patent is a reissue of Mucosis’ US Patent No. 9,060,975 (“reset patent”). The granted patent contains twenty-five claims including thirteen original as well as modified claims of the reset patent plus twelve additi...

April 5, 2019

#ReSViNET , the Respiratory Syncytial Virus Network, selected the recent publication in AJRCCM on the SynGEM Phase I clinical trial as paper of the month March. The study which was executed by Imperial College London, showed that #SynGEM is safe and capable of inducing long term immune responses. A commentary published in the same journal suggested to test the vaccine in a human challenge study. The author manuscript can now be downloaded free of charge from the ReSViNET website

March 6, 2019

SynGEM a needle-free nasal spray vaccine against respiratory syncytial virus


SynGEM shown to be safe and immunogenic in healthy adults


SynGEM the first non-replicating intranasal RSV subunit vaccine to induce persistent antibody responses in humans

Groningen, the Netherlands, March 6, 2019 – Virtuvax B.V. and the trustee of biotech company Mucosis B.V., Mr. Holtz LLM today announce the results of a first-in-human study of the intranasal Respiratory Syncytial Virus (RSV) vaccine candidate, SynGEM. The study was executed by Imperial College London. Results of the study have been posted (in press) on the website of the American Journal of...

February 27, 2019

A new publication in the American Journal of Respiratory and Critical Care Medicine, headed by senior author prof. Louis Bont of UMC Utrecht makes a plea to consider further development of the SynGEM vaccine. Commenting on the results of the SynGEM RSV clinical trial, the authors indicate that the fail-fast approach that has been adopted by pharmaceutical industry, makes a challenging endeavor for development of RSV vaccines. Applying the fail-fast approach, the SynGEM vaccine was evaluated based on early results, generated until 56 days after start of the clinical trial. These early results were found inconclusive and consequently funding of Mu...

February 13, 2019

Today phase I clinical trial data of the Mucosis intranasal RSV F protein vaccine were published on-line. The vaccine was shown to be safe and immunogenic and was shown to induce long-lasting anti-RSV antibodies in healthy adults despite high pre-existing antibody levels. The study was designed as a phase I, randomised, double-blind, placebo-controlled trial in 48 healthy volunteers aged 18-49 year and was executed by Imperial College London. Results were published in the high rated journal AJRCCM. 

The vaccine was developed by Mucosis (NL) and incorporates an RSV-F protein with mutations to maint...

September 19, 2018

Virtuvax consults in vaccine development and provides biosimilar and vaccine technologies. A most recent one, is the prefusion RSV-F vaccine technology. If you are interested, I would be most interested to meet you at the developing countries vaccine manufacturers network (DCVMN) annual meeting in Kunming, China, from October 29 - 31 2018.

Tags: vaccine development, disruptive technology, biosimilar, monoclonal antibody, vaccine technology, DCVMN, Kunming, vaccine consultancy, RSV, pre-fusion RSV-F, RSV vaccine, pneumococcal vaccine

May 12, 2017

Virtuvax will attend Bionnale 2017, 16 & 17th May 2017 in Berlin Germany. You can meet us there, discuss matchmaking and/or other opportunities in vaccine development. You may connect with us at the event or leave us a post directly.

Virtuvax is actively seeking partnerships for the next innovation in vaccine development. Virtuvax has expertise in vaccine development, designing business cases and consortia for fast and effective development of vaccine technology. In addition, we may support your organization with business development for valorisation of your innovative technology or biosimilar via our networks in Europe and Asia. 

February 14, 2017

21st and 22nd February our team will be present in Paris at the scientific community meeting of CEPI in which the urgency for action and the possibilities for vaccine development against global epidemic threats will be highlighted. We are looking forward to fruitful discussions on vaccine development to combat emerging infections and initiate collaborations with CEPI partners. For more information about CEPI and the event: www.cepi.net

February 14, 2017

Read the article written by Louis Garguilo of Outsourced Pharma about innovation in the vaccine industry and the role of our company Virtuvax. Garguilo talked with Virtuvax’ CEO Ernst Soethout on innovation in the vaccine industry, on the intended role of Virtuvax for start-ups and even on skating. The result is a snappy interview, please find a link here.

November 30, 2016

Virtuvax will attend the BioWin Day 2016, 8th December 2016 in Louvain-la-Neuve in Belgium. You can meet us there, discuss matchmaking and/or other opportunities in vaccine development. Virtuvax helps in vaccine development, assists in designing your business case or may valuate the vaccine technology you wish to invest in. For scheduling a F2F meeting during the event you can use the portal of BioWinDay after registration. Of course we also welcome you to contact us directly by phone or e-mail.

Please reload

Virtuvax News

  • LinkedIn Social Icon
  • Twitter Social Icon

© 2016-2017 by Virtuvax BV, The Netherlands